Agfa-Gevaert NV: Share buyback program – regulated information
Mortsel, Belgium – March 28, 2022 – 5:40 p.m. CET
Within the framework of the share buyback program which was announced in the press release of March 10, 2021, Agfa-Gevaert NV proceeded with the purchase of own shares on the market of Euronext Brussels.
The authorization to acquire own shares was granted to the Board of Directors by the Extraordinary General Meeting of Shareholders of May 12, 2020.
Agfa-Gevaert NV has requested a financial intermediary to repurchase Agfa-Gevaert shares for a maximum amount of 50,000,000 Euro on its behalf under the terms of an initial discretionary mandate agreement with validity until March 31, 2022, effective as from April 1, 2021.
On March 8, 2022, the Board of Directors decided that the 2021 Share Buyback will be extended through March 31, 2023 (the ‘Extended Share Buyback Program 2021’).
As a result of the decision of the Board of Directors on March 9, 2021, the Company, by notarial deed dated December 28, 2021, cancelled a total of 2,288,302 treasury shares. This decision was taken in accordance with the authorization granted to the Board of Directors by the Extraordinary General Meeting of Shareholders on May 12, 2020. As a consequence, the new number of outstanding shares (denominator) is 160,506,706.
On transaction date March 25, 2022, the Agfa-Gevaert Group held 2,233,718 own shares, which represents 1.39% of the total number of shares of the Group.
Detailed operations per day:
|Transaction date||Number of |
|March 21, 2022||62,100||3.4307||3.4100||3.4500||213,046.47|
|March 22, 2022||59,994||3.5285||3.3950||3.5750||211,688.83|
|March 23, 2022||60,301||3.5342||3.4900||3.5750||213,115.79|
|March 24, 2022||59,010||3.5491||3.5100||3.5800||209,432.39|
|March 25, 2022||64,500||3.6266||3.5800||3.6550||233,915.70|
Since the beginning of the share buyback program until March 25th, 2022, based on the transaction date, the Agfa-Gevaert Group bought 9,478,202 own shares, representing 5.65% of the total outstanding shares on April 1, 2021.
The Agfa-Gevaert Group is a leading company in imaging technology and IT solutions with over 150 years of experience. The Group holds four divisions: Radiology Solutions, HealthCare IT, Digital Print & Chemicals and Offset Solutions. They develop, manufacture and market analogue and digital systems for the healthcare sector, for specific industrial applications and for the printing industry. In 2021, the Group realized a turnover of 1,760 million Euro.
Director Corporate Communication
T +32 (0) 3 444 71 24
Corporate Press Relations Manager
T +32 (0)3/444 80 15
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Joint Press Release – Kalera and Agrico Announce Effectiveness of Registration Statement, Waiver of Minimum Cash Condition and Extraordinary General Meetings for Proposed Business Combination16.5.2022 08:00:00 CEST | Press release
Extraordinary general meeting of Kalera shareholders (the “Kalera Special Meeting”) and extraordinary general meeting of Agrico shareholders (the “Agrico Special Meeting” and, together with the Kalera Special Meeting, the “Special Meetings”) to approve the proposed business combination of Kalera and Agrico expected to be held on June 27, 2022. Record date for the Kalera Special Meeting is June 6, 2022 (the “Kalera Record Date”); Record date for the Agrico Special Meeting is May 12, 2022 (the “Agrico Record Date” and, together with the Kalera Record Date, the “Record Dates”).Kalera shareholders as of June 6, 2022 voting by proxy should submit their vote by June 22, 2022.Agrico shareholders as of May 12, 2022 voting by proxy should submit their vote by 10:00 a.m., Eastern Time on June 25, 2022.Kalera has waived the minimum cash closing condition. Despite the waiver of the condition, if the minimum cash condition is not satisfied upon the consummation of the business combination, Agrico’s
Inventiva secures a €50 million credit facility from the European Investment Bank16.5.2022 08:00:00 CEST | Press release
This credit facility is intended to support the progress and expansion of Inventiva’s pipelineThe credit facility consists of two tranches of €25 million eachCredit agreement is part of the European Investment Bank’s strategy to support biotech companies developing a high-level of expertise in various therapeutic areas with significant unmet medical needs Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the signing of a €50 million bullet credit facility agreement with the European Investment Bank (“EIB”). The Company plans to use the facility toward its preclinical and clinical pipeline, including to help fund a portion of its Phase III clinical trial of lan
Immunicum AB: Immunicum tillkännager positiva interimsresultat från ADVANCE II-studie i AML-underhållsbehandling16.5.2022 08:00:00 CEST | Pressemelding
Analys av primärstudiens effektmått slutfördes med 7 patienter som visade ett mätbar restsjukdom (MRD)-svar, varav 5 patienter konverterade från MRD+ till MRD- och 2 patienter som visade en avsevärd, minst 10-faldig, minskning av MRD efter behandling med DCP-001Efter en medianuppföljningsperiod på 14,3 månader har medianen för återfallsfri överlevnad (RFS) och total överlevnad (OS) ännu inte uppnåtts.Estimerad RFS vid 6 månader baserad på för närvarande tillgänglig data är 83,7% och estimerad 6-månaders OS är 97,0%Immunicum planerar att presentera fler uppdateringar av överlevnadsdata, inklusive RFS och OS, samt immunövervakningsdata under Q4 2022Företaget håller konferenssamtal och webbsändning i dag kl. 14:00 CET (8:00am ET, 1.00pm GMT) Immunicum AB (“Immunicum” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på behandlingar mot tumörrecidiv och svårbehandlade etablerade tumörer, tillkännagav idag uppdaterade interimsresultat från det pågående ADVANCE II kliniska test som utvärder
Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment16.5.2022 08:00:00 CEST | Press release
Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a substantial, at least 10-fold reduction in MRD following treatment with DCP-001After a median follow-up period of 14.3 months, median relapse-free survival (RFS) and overall survival (OS) have not yet been reachedThe estimated 6-month RFS based on the currently available data is 83.7% and the estimated 6-month OS is 97.0%Immunicum plans to present further updates on survival data including RFS and OS, as well as immunomonitoring data in Q4 2022Company to host conference call and webcast today at 14:00 CET (8am ET, 1pm GMT) Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, announced today updated interim results from the ongoing ADVANCE II clinical trial evaluating the company’s lead developmen
Energy partnership agreement between Vantaa Energy and SATO supports the achievement of SATO’s carbon neutrality target16.5.2022 08:00:00 CEST | Press release
SATO Corporation Press release 16 May 2022 at 9:00 am In February 2022, Vantaa Energy and SATO signed an energy partnership agreement that aims to support the achievement of SATO’s carbon neutrality target by 2030. Vantaa Energy leads the way in climate-friendly energy production and enables smooth everyday life for its customers by constantly developing climate-friendly energy services throughout the property lifecycle. SATO is one of Finland’s largest rental housing providers and makes carefree and sustainable rental housing available for its customers. The purpose of the cooperation between Vantaa Energy and SATO is to together promote and develop carbon-neutral energy solutions for the heating and cooling of buildings as well as new innovative ways to reduce energy consumption so that SATO will reach its targets in line with its strategy. Improving the energy efficiency of properties cuts heating costs and is one of the most important actions taken by SATO to curb climate change an